IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,106.00
Bid: 12,118.00
Ask: 12,122.00
Change: 86.00 (0.72%)
Spread: 4.00 (0.033%)
Open: 12,062.00
High: 12,182.00
Low: 12,032.00
Prev. Close: 12,020.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

21 May 2014 11:28

RNS Number : 6882H
Bank of America Merrill Lynch
21 May 2014
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Pfizer Inc

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - US7170811035

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

5,573,264

0.087%

7,501,833

0.118 %

(2)

Derivatives (other thanoptions):

100,000

0.0%

0.821%

(3)

Options and agreements topurchase/sell:

11,551,000

0.181%

17,529,400

0.275 %

TOTAL:

17,224,264

0.27%

25,031,233

0.39%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Purchase

14,902

29.25 USD

Common - ISIN US7170811035

Purchase

3,941

29.28 USD

Common - ISIN US7170811035

Purchase

100

29.365 USD

Common - ISIN US7170811035

Purchase

2,200

29.37 USD

Common - ISIN US7170811035

Purchase

6,000

29.38 USD

Common - ISIN US7170811035

Purchase

100

29.395 USD

Common - ISIN US7170811035

Purchase

703

29.4 USD

Common - ISIN US7170811035

Purchase

2,200

29.41 USD

Common - ISIN US7170811035

Purchase

181

29.481 USD

Common - ISIN US7170811035

Purchase

2,976

29.49 USD

33303

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Sale

28,310

29.25 USD

Common - ISIN US7170811035

Sale

3,941

29.28 USD

Common - ISIN US7170811035

Sale

5,000

29.315 USD

Common - ISIN US7170811035

Sale

12,790

29.32 USD

Common - ISIN US7170811035

Sale

1,000

29.323 USD

Common - ISIN US7170811035

Sale

8,134

29.325 USD

Common - ISIN US7170811035

Sale

15,300

29.33 USD

Common - ISIN US7170811035

Sale

1,000

29.333 USD

Common - ISIN US7170811035

Sale

4,200

29.335 USD

Common - ISIN US7170811035

Sale

13,200

29.34 USD

Common - ISIN US7170811035

Sale

200

29.345 USD

93075

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN US7170811035

Swaps

Short

181

29.484 USD

Common - ISIN US7170811035

Swaps

Long

824

29.319 USD

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - GB0009895292/ ADR - US0463531089

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

9,116

0.001%

11,677

0.001 %

(2)

Derivatives (other thanoptions):

0

0%

0

0%

(3)

Options and agreements topurchase/sell:

135,200

0.011%

102,700

0.008 %

TOTAL:

144,316

0.011%

114,377

0.009%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Purchase

1,100

72.24 USD

ADR - ISIN US0463531089

Purchase

442

72.25 USD

ADR - ISIN US0463531089

Purchase

1,600

72.26 USD

ADR - ISIN US0463531089

Purchase

200

72.27 USD

3342

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Sale

3,964

72.2 USD

3,964

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOABMMTMBTTBFI
Date   Source Headline
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes
18th Jul 20167:00 amRNSTAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14th Jul 201612:07 pmRNSSecond Price Monitoring Extn
14th Jul 201612:02 pmRNSPrice Monitoring Extension
13th Jul 20167:00 amRNSAZ resolves Faslodex patent litigation in the US
1st Jul 20165:30 pmRNSTotal Voting Rights
28th Jun 20167:00 amRNSZavicefta approved in EU
23rd Jun 20167:00 amRNSAstraZeneca updates on Flumist vaccine in the US
14th Jun 20163:00 pmRNSDirector/PDMR Shareholding
9th Jun 20167:03 amRNSAZ agreement with Aspen for anaesthetics portfolio
3rd Jun 20167:00 amRNSAZ completes US licensing agreement with Ironwood
2nd Jun 20167:00 amRNSAZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
1st Jun 201612:00 pmRNSBlock listing Interim Review
1st Jun 201611:30 amRNSTotal Voting Rights
27th May 201612:36 pmRNSPOSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27th May 20167:03 amRNSPositive results from AstraZeneca Faslodex trial
27th May 20167:00 amRNSAstraZeneca receives CRL from US FDA for ZS-9
23rd May 20164:00 pmRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSTOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17th May 20167:00 amRNSPOSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12th May 20167:00 amRNSSELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11th May 20165:30 pmRNSPublication of Final Terms
9th May 20165:35 pmRNSLaunch and pricing of EUR2.2bn bond issues
5th May 20163:00 pmRNSPublication of a Prospectus
3rd May 20161:30 pmRNSTotal Voting Rights
3rd May 20167:01 amRNSAstraZeneca completes divestment of Imdur
3rd May 20167:00 amRNSAZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29th Apr 20165:30 pmRNSResult of AGM
29th Apr 201612:46 pmRNSPOSITIVE CHMP OPINION FOR CAZ AVI
29th Apr 20167:00 amRNSAZN: 1st Quarter Results
28th Apr 20169:00 amRNSNotice of Results
26th Apr 20169:29 amRNSAZ enters US licensing agreement with Ironwood
26th Apr 20167:01 amRNSBEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
8th Apr 20167:00 amRNSAZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
1st Apr 201611:30 amRNSTotal Voting Rights
29th Mar 20167:00 amRNSTAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24th Mar 20163:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20167:00 amRNSAZ reports results from Brilinta stroke trial
18th Mar 201610:30 amRNSNotice of AGM
8th Mar 20166:29 pmRNSFiling of Form 20-F with SEC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.